ABSTRACT Although the field of cancer immunotherapy is intensively investigated, there is still a need for generic strategies that allow easy, mild and efficient formulation of vaccine antigens.
association with dendritic cells, showing enhanced cellular uptake and antigen cross-presentation to CD8 T-cells.
INTRODUCTION
Dendritic cells (DCs) were first described by Ralph Steinman and co-workers as heterogeneous, large stellate cells that are potent stimulators of the immune system with a much higher antigen presentation capacity compared to other cell subclasses such as macrophages and Blymphocytes. 1, 2 This discovery has led to major insights in how the immune system interacts with foreign material, revealing dendritic cells as the critical factor in the interplay between the innate and the adaptive immune response. 3, 4 DCs are the most potent class of antigen presenting cells (APCs) of the immune system and have the capacity to efficiently recognize pathogens, process and present these foreign antigens to T-lymphocytes leading to activation and proliferation of adaptive immune responses. 5, 6 Presentation of antigens on the cell surface of DCs is mediated by major histocompatibility complex (MHC) peptides, either MHC-I or MHC-II. Intracellular antigens are normally restricted to MHC-I presentation and can activate cytotoxic CD8 [7] [8] [9] However, DCs are also able to present extracellular antigens via MHC-I, through a process called cross-presentation. 10, 11 CTLs can recognize and eliminate malignancies by release of proteases, i.e. perforins and granzymes. 13, 14 Therefore cancer immunotherapy, focusing on stimulating DCs with tumor-associated antigens [15] [16] [17] [18] is a promising strategy that aims for harnessing the patient´s immune system without facing the ubiquitous side effects of chemo-and radiotherapy 3, 12 In this regard, formulating protein antigens into particulate carriers is highly attractive as this dramatically promotes cross-presentation relative to soluble antigens. 15, [19] [20] [21] [22] Sub-micron particles are preferred over bigger ones due to their higher tissue mobility and by consequence ability to target different DC subsets. On the one hand, peripheral migratory DCs can recognize and take up particles at their injection site followed by lymphatic transport to the lymph nodes and antigen-presentation to Tcells. On the other hand, only small nanoparticles, in the sub 200 nm range, will additionally drain to the lymph nodes via passive diffusion into the lymphatics and also target lymph-node resident DCs. [23] [24] [25] [26] In this paper we report on a generic strategy for the formulation of antigens into nano-scaled polymeric conjugates based on co-polymers of N-hydroxypropyl methacrylamide (HPMA) with 3-aminopropyl methacrylamide (APMA). The neutral hydrophilic HPMA moieties provide water solubility and biocompatibility. [27] [28] [29] Additionally, the APMA units will be used to introduce pyridyldisulfide moieties for reversible protein conjugation via disulfide formation and enhancement of cell uptake by interaction with exofacial thiols.
30, 31 Figure 1 shows a schematic representation of the concept. UV-VIS spectrophotometry. UV-VIS spectra were recorded on a Shimadzu UV-1650PC spectrophotometer in 1 cm x 1 cm quartz cells.
Dynamic light scattering (DLS)
. DLS analyses were performed on a Zetasizer Nano S (Malvern Instruments Ltd., Malvern, U.K.) with a HeNe laser (λ = 633 nm) at a scattering angle of 173°. 
Synthesis

Synthesis of poly(HPMA-PDS).
To a 5 mg/mL solution of poly(HPMA-co-APMA) in a phosphate buffered saline (PBS) 1.5 M excess of DMTMM was added followed by an equimolar amount of PDPA dissolved in DMSO. The reaction was stirred overnight for 24 h at room temperature followed by purification via dialysis against deionized water (MWCO 3.5 kDa) for 24 h and lyophilization. The synthesis was confirmed via 1 H NMR analysis. 
Cell
MTT assay
Cell toxicity was measured by seeding DC2.4 in 96 well plates at a density of 50000 cells/mL in complete RPMI medium (total volume 100 μL) 1 day prior to addition of increasing concentrations of poly(HPMA-co-APMA) in PBS. Subsequently the cells were cultured for 24 h followed by addition of 40 μL of the MTT reagent (1 mg/mL). After an incubation period of 2-3 h the formed formazan crystals were dissolved in 100 μL of a 10 % m/v SDS/0.01 M HCl solution overnight protected from light. The absorbance was measured by a microplate reader at 570 nm. As a negative and positive control PBS buffer and DMSO respectively were added to the wells.
Synthesis of OVA-SATP. Protected thiol groups were introduced via interaction with SATP.
First a 120 µM solution of ovalbumin (OVA) was prepared in PBS pH 7,2. Second, SATP dissolved in dry DMSO was added in different molar ratios of SATP to OVA, i.e. 1:5, 1:10, 1:20, 1:50. After incubation of 45 min at room temperature the unreacted fraction was eliminated via a disposable PD10 column. The pure fractions of protein were distinguished from the waste fractions by UV spectrophotometry followed by lyophilization. Quantification of the introduced thiol percentage was assessed by the trinitrobenzene sulfonic acid assay(TNBSA) preceded by deprotection of the thiols in a deacetylation PBS buffer pH 7,2 containing 0.05 M hydroxylamine and 0.025 mM Na2EDTA.
TNBSA
The residual amine content of OVA after SATP substitution was determined by the (2,4,6-trinitrobenzene sulfonic acid assay (TNBSA) according to the manufacturers' instructions. First OVA and OVA-SATP were dissolved in a 0.1 M sodium bicarbonate buffer pH 8.5 at 50 μg/mL followed by addition of 0.25 mL of a 0.01 % TNBSA solution to 0.5 mL of each sample. After incubation of 2 hours at 37 °C 0.25 mL 10 % SDS and 0.125 mL 1 N HCl were added.
Subsequently, absorbance was measured at 335 nm. After 24 h incubation the cells were dissociated using cell dissociation buffer followed by centrifugation for 5 min at 200 G at 0 °C. After resuspension, the samples were stored on ice and measured by the BD Accuri C6 flow cytometer. The data was analyzed using FlowJo. CO2 for 7 days. To ensure optimal bmDC growth, fresh medium containing 20 ng/mL GM-CSF was added on day 3 and on day 6 the medium was refreshed. On day 7 the bmDCs were isolated and pulsed with the test compounds containing 0.2, 2 and 5 mg/mL OVA followed by co-culture with CFSE-labeled OVA specific transgenic CD8 T-cells, according to previously described protocols. 35 
Gel electrophoresis (SDS-PAGE
RESULTS AND DISCUSSION
Synthesis and modification of poly(HPMA-co-APMA).
Co-polymerization of HPMA and APMA was performed by reversible addition-fragmentation transfer (RAFT) polymerization according to Zhu Qin et al. 32 for a targeted degree of polymerization (DP) of 100 repeating units (corresponding to a target molecular weight of 14 kDa) composed of 80 HPMA repeating units and 20 APMA repeating units. Being a controlled radical polymerization technique, RAFT yields access to polymers with a well-defined chain length and a low dispersity 36, 37 , which is of interest to obtain polymers with a molecular weight below the renal clearance threshold that can be eliminated from the body. Subsequently we engineered antigen-binding properties into the polymers ( Figure 3A) . First, we B exchange with cell surface thiols can enhance cellular uptake and can also trigger dissociation of disulfides. 30, 31 The potential cytotoxicity of the residual amine groups on the poly(HPMA-PDS), was assessed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability assay on the immortalized DC2.4 cell line for increasing concentrations of poly(HPMAco-APMA). As shown in Figure 2B , up to a polymer concentration of 0.2 mg/mL, no cytotoxicity is observed, evinced by a cell viability above 70%. In further experiments polymer concentrations well below this threshold (concentration range between 0.0011 mg/mL-0.017 mg/mL) were used to ensure optimal cell viability during these experiments.
Antigen modification with protected thiols.
Antigen conjugation to poly(HPMA-PDS) requires the presence of free thiols on the protein backbone for thiol-disulfide exchange with the PDS moieties. As the composition of every protein differs, variable conjugation efficiency is likely for every other antigen. In addition, it is possible that the amount of thiols per protein will not be sufficient to afford efficient formulation of the respective antigen into nano-conjugates. Therefore we opted to generalize the conjugation strategy.
In this regard, we introduced protected thiols onto lysine residues that are more abundantly present on proteins than cysteines. As a model protein antigen we used ovalbumin (OVA) because the latter contains peptide sequences that are recognized by the murine immune system as CD4 and CD8 epitopes. Moreover, a wide variety of in vitro and in vivo tools are available for immunological assessment of OVA based vaccine formulations. OVA was reacted with a molar ratio of OVA to S-acetylthiopropionate N-succinimidyl ester (SATP) of 1 to 15. This compound substitutes primary amines on lysine residues with acetylated thiols that can be deprotected in situ poly(HPMA-PDS). The decrease in free amines was quantified by spectrophotometry using the (2,4,6-trinitrobenzene sulfonic acid) assay (TNBSA), thereby indicating 78 % of all available lysines to be substituted (Figure 3C ). 
Antigen conjugation.
In a first series of experiments, the polymer-conjugation efficiency of OVA-SATP was compared versus unsubstituted OVA. SDS-PAGE was used to assess protein conjugation of poly(HPMA-PDS) to OVA and OVA-SATP. For unsubstituted OVA, no difference could be observed upon incubation of the protein with the polymer. In contrast, the free OVA band disappears almost completely when OVA-SATP is used as shown in Figure 4 . This confirms that SATP substitution strongly increases the polymer-protein conjugation efficiency. Interestingly three distinct bands appear that correspond either to OVA that is ligated to several polymer strands or vice versa, along with a broad spread of higher molecular weight bands. These data suggest that besides polymers being grafted onto the protein, also polymeric crosslinking among different proteins occur. Figure 4B ) revealed the presence of small conjugates without extensive inter-particle crosslinking, as evidenced by both the size distribution and the correlation curves. This property is of importance with regard to tissue mobility in vivo. The required ratio of polymer to OVA-SATP to yield optimal conjugation was determined by visualization of the conjugation efficiency of different molar ratios of OVA-SATP to poly(HPMA-PDS), by SDS-PAGE. Figure 5 indicates that approximately 100% conjugation can be already obtained at an equimolar ratio of OVA-SATP to poly(HPMA-PDS). Therefore, we decided to use a ratio of OVA to polymer of 1:1 in further experiments. To assess the reversible nature of the disulfide bonds formed between OVA-SATP and the poly(HPMA-PDS), SDS-PAGE was performed in presence and absence of 2-mercaptoethanol as a reducing agent. As shown in Figure   5 , in presence of 2-mercaptoethanol, the band corresponding to OVA-SATP reappears again as a single protein band confirming the reversibility of the conjugation. 
Dynamic light scattering (DLS;
In vitro characterization.
Next we aimed at investigating the effect of polymer conjugation on the uptake of OVA by DCs. To identify the reason for which polymer-conjugated OVA shows higher uptake than soluble OVA, we pulsed DCs with soluble OVA and poly(HPMA-PDS) separately at 4°C. Under these conditions, energy dependent uptake mechanisms are blocked. As shown in Figure 7A , soluble OVA is not associated with the DCs at 4°C, opposed to poly(HPMA-PDS) which does show dosedependent cellular association. Confocal microscopy ( Figure 7B ; overlaying the DIC and the Atto647 channel) confirmed that at 4°C, poly(HPMA-PDS) is indeed bound to the cell membrane.
Taken together, we hypothesize that remaining pyridyldisulfide moieties on the conjugates promote interaction with cysteine residues of cell surface proteins and thereby bind to the cell membrane [29, 30] . 
CONCLUSIONS
To summarize, we have shown in this work that water-soluble HPMA-based RAFT polymers with multiple pending pyridyldisulfide moieties are well suited for protein conjugation, on the condition that these proteins are modified with protected thiols that can be deprotected in situ. The obtained conjugates are stable in aqueous medium and can be disassembled in response to reducing conditions. In vitro experiments on dendritic cells show that the polymer conjugation of a model antigen resulted in an increased cellular uptake, relative to unconjugated protein, which we attribute to thiol-disulfide exchange between remaining pyridyldisulfide moieties and exofacial thiols present on the cell surface. Furthermore, we demonstrate that polymer conjugation increases antigen presentation by bmDCs to CD8 T-cells in vitro. In future research, the effect of polymer conjugation on lymphatic antigen transportation and in vivo immune activation will be studied as well as conjugation of molecular adjuvants to these polymers.
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